### Cerebrovascular Reperfusion: What Do We Have in Common?

### Edward Jauch, MD MS







### **Disclosure Statement of Financial Interest**

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

### **Affiliation/Financial Relationship**

• Grant / Research Support

### Affiliations

### Company


- NIH / NINDS Research funding
   FAST-MAG DSMB
- STOP-IT Study Novo Nordisk (drug in kind)
- PRISMS Study Genentech
- POSITIVE Study Covidiene, Stryker, Penumbra
- BASE Study
   Ischemia Care
- Medical University of South Carolina
- American Heart Association
  - Past president, Stroke Council Guidelines writing group chair ACLS Stroke writing group chair



In Partnership with the ACC Reinventing the Futu Every Year

## **Current State of Stroke**

- Growing global epidemic paralleling increase in cardiovascular disease
  - Share same risk factors
  - Similar need for reperfusion



A regional systems approach key to triaging patients to the level of necessary care
Stroke care has lagged STEMI care by decades





## Phases of AMI Treatment

- Phase 1 1912 1961
   Bed rest, expectant treatment
- Phase 2 1961 1974
   Coronary care units
- Phase 3 1975 present Myocardial reperfusion
- Phase 4 Future
   Reperfusion injury, regeneration





Braunwald, European Heart J: Acute CV Care 2012;1:9-12

### **Development of Acute Stroke Treatments**

400BC Hippocrates described "apoplexy"

- 1920s Contrast angiography developed
- 1950s First carotid endarterectomy performed
- 1960s Doppler ultrasonography developed.
- 1970s Development of computerized tomography (CT) Aspirin shown to prevent stroke
- 1980s Development of magnetic resonance imaging Interventional procedures more aggressive
- 1987 Beginning of NINDS t-PA Pilot trial
- 1990s Carotid enarterectomy proven to prevent stroke





### **Development of Acute Stroke Treatments**

- 1991 Beginning of NINDS t-PA Stroke Trial
- 1993 Stroke units shown to save lives
- 1995 Publication of NINDS t-PA Stroke Trial(s); Start of EMS Trial
- 1996 FDA approval of t-PA for ischemic stroke
- 1999 Publication of PROACT II Trial
- 2000 Publication of Primary Stroke Center recommendations
- 2001 Start of IMS I Trial
- 2004 FDA clearance of Concentric Retriever Get With the Guidelines – Stroke begins
- 2005 Start of IMS III Trial





### **Development of Acute Stroke Treatments**

- 2006 New DRGs for t-PA and thrombectomy
- 2007 AHA Guidelines for stroke system development
- 2008 FDA approves thrombectomy device; ECASS III Stroke drops from 3<sup>rd</sup> to 4<sup>th</sup> leading cause of death
- 2009 AHA guidelines rtPA 3-4 1/2 hr window & telemedicine
- 2011 United Nations Summit on NCD, including stroke AHA guidelines for Comprehensive Stroke Centers
- 2012 JC develops criteria for CSC *Stent retrievers received FDA clearance*2013 Large number of studies reporting neutral results






## Similar Lessons to STEMI Care

- Reperfusion critical
  - Minimize delay
  - Maximize penumbral salvageability
    - Collateral flow
    - Physiologic optimization
- Time to reperfusion
  - Drives clinical outcomes
  - Affects likelihood of a trial success
  - Should drive all system development







CARDIOVASCULAR RESEARCH FOUNDATION At the heart of innovation

## Unique Features in Stroke

Diagnostic challenge

No ECG, no troponin, no echo
Diagnosis of exclusion

Clots vary

Source either embolic or *in situ* thrombotic

- Clot size and location highly variable
- Clot composition complex
- Extremely tight but variable reperfusion window
- Disability primary outcome (vs mortality)






### Time Dependent Benefit of Reperfusion Therapy


### IV rt-PA for Stroke

### **STEMI** Reperfusion



#### Figure 3: Model estimating odds ratio for favourable outcome at 3 months in rt-PA-treated patients compared with controls by OTT


Adjusted for age, baseline glucose concentration, baseline NIHSS measurement, baseline diastolic blood pressure, previous hypertension, and interaction between age and baseline NIHSS measurement.



In Partnership with the ACC Reinventing the Future Every Year

Hacke, *Lancet*. 2004;363:768-74 Tiefenbrunn , *Circulation*. 1992;85:2311-2315

### Time to Reperfusion: IA Treatment




In Partnership with the ACC Reinventing the Future Every Year

Khatri, *Strok*e. 2013 Mazighi, *Lancet Neurology.* 2009



## Impact of Time on Outcome

Comparison of the relative efficacies of thrombolysis in AMI and acute ischemic stroke (with endpoints of death and death and disability) per 1000 patients treated.







## **Current Stroke Care**

- Public education
- Systems development


sixth annual sc heart & stroke care alliance: marking the milestones & mapping the future

- Focus on EMS and Emergency Department care
- Reperfusion drives system
- Specialized hospital-based stroke care
- Early secondary prevention
- Aggressive and early rehabilitation





### Stroke Systems of Care



In Partnership with the ACC Reinventing the Future Every Year

Schwamm, *Circulation.* 2005;111:1078-191 Higashida, *Stroke.* 2013;44



CARDIOVASCULAR RESEARCH FOUNDATION At the heart of innovation

# Stroke Chain of Survival

- Detection:
- Dispatch:
- Delivery:
- Door:
- Data:
- Decision:
- Drug:
- Disposition:

Early recognition Early EMS activation Transport & management ED triage ED evaluation & management Neurology input, therapy selection Thrombolytic, drugs, device Admission or transfer



## Door Emergent Triage Data ED Evaluation (Triad)








In Partnership with the ACC Reinventing the Future












CARDIOVASCULAR RESEARCH he heart of innovation

## **Current ACLS Guidelines**

- Door-to-MD: 10 minutes
- Door-to-Team: 15 minutes
- Door-to-CT scan: 25 minutes
- Door-to-Drug: 60
- Door-to-Unit:

60 minutes 3 hours



25 In Partnership with the ACC Reinventing the Future Every Year

Jauch, ACLS Stroke 2010 NINDS National Symposium on Acute Stroke, 2003



## Decision A Team Approach Drug(s) / Device



tct 25 In Partnership with the ACC Reinventing the Future Every Year



CARDIOVASCULAR RESEARCH FOUNDATION At the heart of innovation

## **Recanalization Strategies**

FDA approved / cleared interventions:

 IV tPA (0-3 hours)
 Approved 1996
 IV tPA (3-4.5 hours)
 Denied request 2012
 2013 AHA Recommends


- Thrombectomy devices Cleared for clot removal

Time Window	0-3 hrs	3-4.5 hrs	3-6 hrs	8 hrs
Options	<ul><li>IV tPA</li><li>Device</li></ul>	<ul><li>IV tPA</li><li>Device</li></ul>	<ul><li>IA Lytic</li><li>Device</li></ul>	• Device





### **Intra-arterial Strategies**




Reinventing the Future Every Year






## Recanalization Trials

### Hypothetical Benefit of Cardiac Reperfusion



### Intraarterial Reperfusion in Stroke





## The Future of Stroke Treatments

- Prevention Prevention Prevention
- Stroke Systems of Care
- Stroke Research
  - Stroke clinical trial networks
  - New diagnostic tools
  - Thrombolytics
  - Intra-arterial approaches
  - Combination agents
  - Refining and defining windows
  - Cerebral protection
  - Surgical
  - Rehabilitation


Neuroimaging, markers ProUK, TNK, rPA, Ancrod IA, specialty catheters, devices Antiplatelets, LMWH Clinically, imaging based Hypothermia, neuroprotection Hemicraniectomy, cell transplant Constraint therapy



Partnership with the ACC einventing the Future lery Year



## **Penumbral Imaging**



## Top $\uparrow$ CBV $\uparrow$ MTT with penumbra $\rightarrow$ small strokeBottom $\downarrow$ CBV $\uparrow$ MTT $\rightarrow$ no penumbra to save $\rightarrow$ big stroke



Majda Thurnher, Medical University of Vienna Parsons, *Neurology*. 2007;68:730–736



CARDIOVASCULAR RESEARCH FOUNDATION At the heart of innovation

### The Future: Full Integration of Care



tct 25 In Partnership with Reinventing Every Year

n Partnership with the ACC Reinventing the Future Every Year Full Recovery Prevention Strategies



art of innovation



### **ASA Policy Recommendations**

### **Recommendations for the Establishment of Stroke** Systems of Care

### Recommendations From the American Stroke Association's Task Force on the Development of Stroke Systems

Stroke

JOURNAL OF THE AMERICAN HEART ASSOCIATION



### Interactions Within Stroke Systems of Care: A Policy Statement From the American Heart Association/American Stroke Association

Randall Higashida, Mark J. Alberts, David N. Alexander, Todd J. Crocco, Bart M. Demaerschalk, Colin P. Derdeyn, Larry B. Goldstein, Edward C. Jauch, Stephan A. Mayer, Neil M. Meltzer, Eric D. Peterson, Robert H. Rosenwasser, Jeffrey L. Saver, Lee Schwamm, Debbie Summers, Lawrence Wechsler and Joseph P. Wood



n Partnership with the ACC Reinventing the Future Every Year

Schwamm, *Circulation* 2005;111:1078-191 Higashida, *Stroke* 2013;44



### Lecture Overview

- Review current state of acute stroke
- Review similarities and differences in cerebrovascular and cardiovascular reperfusion
- Review other acute strategies at improving functional outcomes



